Bristol-Myers Squibb Company (BMY)
| Chiusura precedente | 74,46 |
| Aperto | 74,58 |
| Denaro | 75,40 x 800 |
| Lettera | 75,41 x 1000 |
| Min-Max giorno | 74,57 - 75,52 |
| Intervallo di 52 settimane | 53,22 - 80,59 |
| Volume | |
| Media Volume | 11.754.214 |
| Capitalizzazione | 160,903B |
| Beta (5 anni mensile) | 0,39 |
| Rapporto PE (ttm) | 25,03 |
| EPS (ttm) | 3,01 |
| Prossima data utili | 26 ott 2022 |
| Rendimento e dividendo (forward) | 2,16 (2,88%) |
| Data ex dividendo | 30 giu 2022 |
| Stima target 1A | 81,38 |
- GlobeNewswire
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set
NEW ORLEANS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion
- GlobeNewswire
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE
CEDARHURST, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To learn
- GlobeNewswire
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
NEW ORLEANS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To le
